MedTrace Logo

Screening For First Trimester's Hyperglycemia in High and Low Risk Pregnancy

NCT06064552 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-10-03

No results posted yet for this study

Summary

Glucose intolerance is the commonest medical disorder complicating pregnancy. Hyperglycemia increases the risk of delivering a large for gestational age newborn (LGA) and related complications such as operative delivery, birth trauma and the poor adaptation of the newborn . Maternal risks of GDM include also polyhydramnios, preeclampsia, premature delivery, prolonged labor, uterine atony, postpartum hemorrhage, infection and progression of retinopathy which are the leading global causes of maternal morbidity and mortality .Detection of women at higher risk for GDM early in pregnancy is a desirable goal because interventions such as diet, medication, and exercise may be applied earlier in pregnancy and potentially can reduce later development of GDM or its associated morbidities. Most GDM cases are diagnosed after mid-gestation following an abnormal glucose challenge test (GCT). However, about 10% of patients with GDM can be diagnosed in the first trimester.

Conditions

  • Screening for Hyperglycemia in First Trimester in High and Low Risk Pregnancy

Interventions

DIAGNOSTIC_TEST

blood sugar

High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin. For whom measures normal will be tested by the same method at 20- 24 wks of gestation

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-24
Primary Completion
2024-09-24
Completion
2024-09-24

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06064552 on ClinicalTrials.gov